NovaBridge’s Visara Plans To Develop HT006.2.2 As VIS-102, Second Clinical-Stage Program, Expanding Its Ophthalmology Portfolio Beyond Retinal Vascular Disease Into Ocular Surface Disease

Visara, a subsidiary of NovaBridge Biosciences (NASDAQ: NBP), has secured exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2, which will be branded as VIS-102. This investigational therapy aims to treat neurotrophic keratitis by restoring corneal health and offers a more convenient treatment option. The development of VIS-102 marks Visara's second clinical-stage program, expanding its portfolio into ocular surface disease beyond retinal vascular conditions.